Disclosures “I have no relevant financial relationships with the manufacturers(s) of any...

36
Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services discussed in this CME activity.”

Transcript of Disclosures “I have no relevant financial relationships with the manufacturers(s) of any...

Page 1: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

Disclosures

• “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services discussed in this CME activity.”

Page 2: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.
Page 3: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.
Page 4: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.
Page 5: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

• The Five Domains of Value:• Access• Technical Quality• Functional Status• Service Satisfaction • Cost/price

• Value (V) == A + TQ +FS + SS

C

Page 6: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

The Value In Pediatrics Network“No Secrets is the new rule in my Escape Fire….” Don Berwick

VIP Steering Committee: Matt Garber, MD; Steve Narang, MD, MHCM; Brian Pate, MD; Shawn Ralston, MD Mark Shen.MD

Page 7: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

OUR STORY–

the VIP Network Collaborative

Page 8: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

The Network• Conceived from a thread on the AAP-SOHM

listserv:• Variation leads to waste and poor quality/value• Evidence-base for decisions is often lacking• Institutional culture dictates care• Tension between

• caregiver autonomy• individualization of care• standardization (“cookbook medicine”)

• How do we change the culture?

Page 9: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

The Problem

• Most research conducted in free-standing children’s hospitals attached to academic medical centers

• 70% of children are cared for in NON-children’s hospitals

Page 10: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

The Decision

• A collaborative benchmarking project

• Can we get data from a representative sample (all types of hospitals)?

• Can processes be linked to their outcomes?

• How do you stratify for demographics and risk?

Page 11: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

The Project• Bronchiolitis – a prime target for hospital(ist)s

• #1 discharge ICD-9 diagnosis, excluding birth

• #2 in aggregate costs

• incredible degree of variation

• long track record of unproven therapies

• new evidence-based AAP guidelines

Page 12: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

The Database• Include any institution that cares for hospitalized

children

• Comprehensive demographic information

• Basic administrative data targeting processes and outcomes

Page 13: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

The Data

• A toolkit with ICD-9 codes to capture bronchiolitis in children under 2 years of age

• Exclude children in the PICU, with immunodeficiency, CHD, Asthma, BPD

Page 14: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

The Processes• Percentage of patients receiving any

• Bronchodilator

• Steroids

• CXR

• RSV antigen testing

• CPT

Page 15: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

The Outcomes• Length of stay• Utilization of therapies• Readmit rate within 72 hours• Variable Direct Costs

• Total encounter• Pharmacy• Respiratory• Radiology

Page 16: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

Results• 2009 is the 3rd year of the project• 30 total centers have participated• Gather data on over 3000 admits per year• Programs of widely varying size from 20 to 500+

bronchiolitis admits per year• Validation rules now in place• The typical hospital is a children’s hospital within a

hospital and most participants are teaching programs• LOS 2.5 day and average readmission rate 1.2%

Page 17: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

Program Volume

Page 18: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

Length of Stay

Page 19: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

VDC/encounter

Page 20: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

Bronchodilator Usage

Page 21: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

Bronchodilator Doses per Patient

Page 22: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

Steroid Usage

Page 23: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

CXR Utilization

Page 24: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

Chest Physiotherapy Usage

Page 25: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

So, are we getting better?

• Benchmarking vs. competing against yourself

• Collaboratives

• Awards• Most improved bronchodilator usage• Under 10% award for steroids • Getting to Zero Award for CPT • Consistently Low CXR Usage award

• Resource Sharing

Page 26: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

Behind the Scenes Challenges

• Some data collected manually (chart review)

• Most data collected via hospital administration:

• ICD-9 codes to identify patients

• Financial data to measure process & resource utilization

• Administrative data for outcomes (LOS and readmits)

Page 27: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

Validation

• Chart Review

• 10%; minimum 10; goal ≥ 80% accuracy

• 1 hospital with significant issues – not easily fixed

• Outliers

• 1 hospital with 8% readmit rate (Network range 0-3%)

• Error identified; easily corrected

Page 28: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

The VIP Network Collaborative---• Benchmarking is only the FIRST step in the Escape fire….

• The power of the VIP Network lies in creating Improvement Collaboratives focused on identifying best practices and disseminating knowledge…..

Page 29: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

Global Aims: To Improve Effectiveness of Care (IOM)

To Reduce Waste #2, #7 (LEAN)

VIP Network Collaborative #1Co Chairs: Matt Garber, MD and Beth Robbins, MD

AIM:Reduce the use of inhaled short-acting bronchodilators in children hospitalized with bronchiolitis

Page 30: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

AIM

Reduce the use of inhaled short-acting bronchodilators in children

hospitalized with bronchiolitis

Page 31: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

Method• Implement a treatment protocol for children with

bronchiolitis which uses objective measurements by RT personnel to limit use of SABA therapy to sicker patients who demonstrate a positive response to SABA therapy.

Page 32: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

Measures

• the percentage of children hospitalized for bronchiolitis who receive any SABA therapy

•The average total number of bronchodilator treatments per all hospitalized patients with bronchiolitis

Page 33: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

Goals• To reduce the number of bronchiolitis patients treated with

any bronchodilator medication by 20% from that institution’s baseline or to <=30%

• To reduce the average total number of treatments per patient by 50% from that institution’s baseline

Page 34: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

2 of 5 hospitals with data available Measure Hospital 1 Hospital 2% Pts SABA

Pre

Post

Change

Preliminary

91%

70%

-21%

Final data

75%

49%

-26%

Total doses/pt

Pre

Post

Change

Preliminary

12

7

-42%

Final data

2.5

1.2

-52%

Page 35: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

Conclusions/Change package• Reduction of wasteful therapies can be achieved,

especially when evidence exists, is widely accepted (AAP guidelines) and a measurement tool has been put in place (VIP network)

• Both technical and cultural barriers need to be addressed

• Communication at every level – nurse, RT, PCP, ED attendings, other hospitalists, learners - is needed to address cultural barriers

• New partnerships with RT, RN, IT, CQI, and administration are also needed to address technical barriers

Page 36: Disclosures “I have no relevant financial relationships with the manufacturers(s) of any commercial products(s) and/or provider of commercial services.

Why Collaboratives???

“the subtleties of medical decision-making can be identified and learned. The lessons are hidden. But if we open the book on physicians’ results, the lessons will be exposed. And if we are genuinely curious about how the best achieve their results, he believes they will spread” Atul Gawande, MD